Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Xencor Inc (XNCR) USD0.01

Sell:$30.00 Buy:$57.59 Change: $0.06 (0.18%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$30.00
Buy:$57.59
Change: $0.06 (0.18%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$30.00
Buy:$57.59
Change: $0.06 (0.18%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Contact details

Address:
111 W Lemon Ave
MONROVIA
91016-2809
United States
Telephone:
+1 (626) 3055900
Website:
www.xencor.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XNCR
ISIN:
US98401F1057
Market cap:
$1.95 billion
Shares in issue:
58.32 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Bassil Dahiyat
    President, Chief Executive Officer, Founder and Director
  • John Kuch
    Chief Financial Officer, Senior Vice President
  • John Desjarlais
    Senior Vice President, Research and Chief Scientific Officer
  • Allen Yang
    Senior Vice President, Chief Medical Officer
  • Celia Eckert
    Vice President, General Counsel, Corporate Secretary
  • Jeremy Grunstein
    Vice President of Business Development
  • Eric Kowack
    Vice President, Program Leadership and Strategic Alliances
  • Kirk Rosemark
    Vice President, Regulatory Affairs and Quality Assurance
  • Julie Casciani
    Executive Director - Human Resources

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.